Bioverativ Inc (BIVV) Receives Consensus Rating of “Hold” from Analysts
Bioverativ Inc (NASDAQ:BIVV) has been assigned an average rating of “Hold” from the seventeen research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $60.54.
BIVV has been the subject of several research reports. Zacks Investment Research upgraded shares of Bioverativ from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Morgan Stanley restated an “underweight” rating and issued a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a research note on Monday, October 23rd. Royal Bank Of Canada initiated coverage on shares of Bioverativ in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target for the company. Finally, Evercore ISI initiated coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 price target for the company.
Shares of Bioverativ (NASDAQ BIVV) opened at $50.57 on Monday. Bioverativ has a 1-year low of $40.00 and a 1-year high of $64.41.
Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The company’s revenue for the quarter was up 27.2% compared to the same quarter last year. sell-side analysts forecast that Bioverativ will post 2.45 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $137,000. TCI Wealth Advisors Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $186,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $190,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bioverativ during the 3rd quarter worth $194,000. Finally, ACG Wealth purchased a new stake in shares of Bioverativ during the 3rd quarter worth $205,000. 96.95% of the stock is owned by institutional investors and hedge funds.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.